Download PDF
Thromb Haemost 1989; 61(02): 211-216
DOI: 10.1055/s-0038-1646561
Original Article
Schattauer GmbH Stuttgart

Measurement of Aspirin Concentrations in Portal and Systemic Blood in Pigs: Effect on Platelet Aggregation, Thromboxane and Prostacyclin Production

F Bochner
1   The Department of Clinical and Experimental Pharmacology, University of Adelaide, South Australia, Australia
,
D M Siebert
1   The Department of Clinical and Experimental Pharmacology, University of Adelaide, South Australia, Australia
,
S E Rodgers
2   The Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
,
G H McIntosh
3   The C. S. I. R. O. Division of Human Nutrition, Glenthorne Laboratory O’Halloran Hill, South Australia, Australia
,
M J James
4   The Department of Surgeny, Flinders Medical Centre, Adelaide, South Australia, Australia
,
J V Lloyd
2   The Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
› Author Affiliations
Further Information

Publication History

Received 30 August 1988

Accepted after revision 06 December 1988

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Low doses of enteric-coated aspirin were administered orally to pigs. Plasma aspirin concentrations measured in blood obtained simultaneously from permanent catheters in a systemic artery and portal vein for 6 hours after dosage showed a large variation in the plasma aspirin concentration : time profile between pigs. After 50 mg single dose the ratio of the arterial : portal area under the plasma concentration versus time curve (AUC) was 0.63 ± 0.08 (mean ± SE, n = 6). In three pigs which received all three dosage regimens, the arterial : portal AUC ratios were 0.48 ± 0.05 after 50 mg single dose, 0.52 ± 0.02 after 100 mg single dose and 0.47 ± 0.02 after 100 mg daily for 1 week. Platelet aggregation in response to sodium arachidonate (1.65 mM) was completely abolished after chronic aspirin administration of 100 mg daily. Thromboxane production (pg/ 106 platelets) induced by this stimulus decreased from 536 ± 117 before aspirin to 57 ± 14 after aspirin (mean ± SE, n = 4; p = 0.03). Aortic prostacyclin synthesis, measured as 6-keto PGF1α (ng/disc after 10 min incubation), was 1.66 ± 0.28 (mean ± SE, n = 4) in untreated pigs and 0.95 ± 0.25 (n = 5) in treated pigs (p = 0.07). Results from this study support the idea that a difference between aspirin concentrations in the portal and systemic circulations can be achieved. Whether this can be translated into a clinically useful differential effect on the vessel wall compared to the platelet remains to be determined.

Keywords

Aspirin - Hepatic metabolism - Prostacyclin - Thromboxane
 

  • References

  • 1 Bochner F, Lloyd J. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man. Clin Sci 1986; 71: 625-631
    CrossrefPubMedGoogle Scholar
  • 2 Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
    CrossrefPubMedGoogle Scholar
  • 3 Burch JW, Baenziger NL, Stanford N, Majerus PW. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci USA 1978; 75: 5181-5184
    CrossrefPubMedGoogle Scholar
  • 4 Hanley SP, Cockbill SR, Bevan J, Heptinstall S. Differential inhibition of low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1981; 1: 969-971
    PubMedGoogle Scholar
  • 5 Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med 1981; 304: 76-79
    CrossrefPubMedGoogle Scholar
  • 6 Weksler BB, Tack-Goldman K, Subramanian VA, Gay Jr WA. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 1985; 71: 332-340
    CrossrefPubMedGoogle Scholar
  • 7 Cerletti C, Marchi S, Lauri D, Domanin M, Lorenzi G, Urso R, Dejana E, Latini R, de Gaetano G. Pharmacokinetics of enteric- coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans. Clin Pharmacol Ther 1987; 42: 175-180
    CrossrefPubMedGoogle Scholar
  • 8 Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60: 635-642
    CrossrefPubMedGoogle Scholar
  • 9 Herd CM, Rodgers SE, Lloyd JV, Bochner F, Duncan EM, Tunbridge LJ. A dose-ranging study of the antiplatelet effect of enteric coated aspirin in man. Aust N Z J Med 1987; 17: 195-200
    CrossrefPubMedGoogle Scholar
  • 10 Ali M, McDonald JW D, Thiessen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9-13
    CrossrefPubMedGoogle Scholar
  • 11 Ross-Lee LM, Elms MJ, Cham BE, Bochner F, Bunce IH, Eadie MJ. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 1982; 23: 545-551
    CrossrefPubMedGoogle Scholar
  • 12 Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367-374
    CrossrefPubMedGoogle Scholar
  • 13 Roberts MS, McLeod LJ, Cossum PA, Vial JH. Inhibition of platelet function by a controlled release acetylsalicylic acid formulation - single and chronic dosing studies. Eur J Clin Pharmacol 1984; 27: 67-74
    CrossrefPubMedGoogle Scholar
  • 14 Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379-385
    CrossrefPubMedGoogle Scholar
  • 15 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase N Engl J Med 1984; 311: 1206-1211
    CrossrefPubMedGoogle Scholar
  • 16 Bochner F, Williams DB, Morris P, Siebert DM, Lloyd JV. Pharmacokinetics of low dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988; 35: 287-294
    CrossrefPubMedGoogle Scholar
  • 17 Jakubowski JA, Stampfer MJ, Vaillancourt R, Faigel D, Deykin D. Low-dose enteric-coated aspirin: a practical approach to continuous- release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med 1986; 108: 616-621
    PubMedGoogle Scholar
  • 18 Cerletti C, Gambino MC, Garattini S, de Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels J Clin Invest 1986; 78: 323-326
    CrossrefPubMedGoogle Scholar
  • 19 Gambino MC, Passaghe S, Chen ZM, Bucchi F, Gori G, Latini R, DeGaetano G, Cerletti C. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portacaval shunt in rats. J Pharmacol Exp Ther 1988; 245: 287-290
    PubMedGoogle Scholar
  • 20 Topping DL, Illman RJ, Taylor MN, McIntosh GH. Effects of wheat bran and porridge oats on hepatic portal venous volatile fatty acids in the pig. Ann Nutr Metab 1985; 29: 325-331
    CrossrefPubMedGoogle Scholar
  • 21 NHMRC/CSIRO/AAC. Code of practice for the care and use of animals for experimental purposes. Australian Government Publishing Service; Canberra: 1985
    Google Scholar
  • 22 McIntosh GH, Pointon A. The Kangaroo Island strain of pig in biomedical research. Aust Vet J 1981; 57: 182-185
    CrossrefPubMedGoogle Scholar
  • 23 Cham BE, Ross-Lee L, Bochner F, Imhoff DM. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther Drug Monit 1980; 2: 365-372
    CrossrefPubMedGoogle Scholar
  • 24 Siebert DM, Bochner F. Determination of plasma aspirin and salicylic acid concentrations after low aspirin doses by high-performance liquid chromatography with post-column hydrolysis and fluorescence detection. J Chromatogr 1987; 420: 425-431
    CrossrefPubMedGoogle Scholar
  • 25 Watts SE, Tunbridge LJ, Duncan EM, Lloyd JV. Storage of platelets for tests of platelet function: comparison of two methods of pH control. Thromb Res 1985; 37: 73-83
    CrossrefPubMedGoogle Scholar
  • 26 Watts SE, Tunbridge LJ, Smith K, Lloyd JV. Storage of platelets for tests of platelet function: effects of temperature on platelet aggregation, platelet morphology and liberation of β-thromboglobulin. Thromb Res 1986; 44: 365-376
    CrossrefPubMedGoogle Scholar
  • 27 Cazenave J-P, Packham MA, Mustard JF. Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med 1973; 82: 978-990
    PubMedGoogle Scholar
  • 28 James MJ, Walsh JA. Effects of aspirin and alcohol on platelet thromboxane synthesis and vascular prostacyclin synthesis. Thromb Res 1985; 39: 587-593
    CrossrefPubMedGoogle Scholar
  • 29 Inoue M, Morikawa M, Tsuboi M, Sugiura M. Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn J Pharmacol 1979; 29: 9-16
    CrossrefPubMedGoogle Scholar
  • 30 Levy G, Angelino NJ. Hydrolysis of aspirin by rat small intestine. J Pharm Sci 1968; 57: 1449-1450
    CrossrefPubMedGoogle Scholar
  • 31 Spenney JG. Acetylsalicylic acid hydrolase of gastric mucosa. Am J Physiol 1978; 234: 606-610
    PubMedGoogle Scholar
  • 32 Addonizio Jr VP, Edmunds Jr LH, Colman RR. The function of monkey (M. mulatta) platelets compared to platelets of pig, sheep, and man. J Lab Clin Med 1978; 91: 989-997
    PubMedGoogle Scholar